Literature DB >> 30853755

Present and Future Prospect of Small Molecule & Related Targeted Therapy Against Human Cancer.

Akshat Pathak1, Sanskriti Tanwar2, Vivek Kumar2, Basu Dev Banarjee3.   

Abstract

Cancer is uncontrolled cell growth guided by deregulation of cell growth network. Subsequently, alteration in genes occurs which influences expression (down-regulation of tumor suppressor genes and/or up-regulation of proto-oncogene) of these prominent cell growth proteins. Protein targeting has emerged as a hope against cancer. These therapies work by inhibiting or up regulating the target proteins through agents specific for treatment of deregulated proteins. Targeted cancer therapies are more favorable for cancers like lung, colorectal, breast, lymphoma and leukemia as they focus on particular molecular changes unique to a specific cancer. As researchers scrutinize and comprehend the cell changes that initiate cancer, they are better able to design promising therapies targeting these changes or nullify their effect. In present study we have assessed prospects of significant proteins which are known to be targeted by number of small molecules and related drugs for effective treatment of various forms of cancer. Moreover, we also addressed the efficacies of these drugs toward the cancer treatment and future challenges in their development as this information is lacking in previously published work.

Entities:  

Keywords:  Cancer; Protein-targeting; Small-molecules; Therapy

Year:  2018        PMID: 30853755      PMCID: PMC6407887     

Source DB:  PubMed          Journal:  Vivechan Int J Res        ISSN: 0976-8211


  90 in total

Review 1.  Genome maintenance mechanisms for preventing cancer.

Authors:  J H Hoeijmakers
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

2.  Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck.

Authors:  R Knecht; R Elez; M Oechler; C Solbach; C von Ilberg; K Strebhardt
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

3.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Authors:  Dirk B Mendel; A Douglas Laird; Xiaohua Xin; Sharianne G Louie; James G Christensen; Guangmin Li; Randall E Schreck; Tinya J Abrams; Theresa J Ngai; Leslie B Lee; Lesley J Murray; Jeremy Carver; Emily Chan; Katherine G Moss; Joshua O Haznedar; Juthamas Sukbuntherng; Robert A Blake; Li Sun; Cho Tang; Todd Miller; Sheri Shirazian; Gerald McMahon; Julie M Cherrington
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

4.  Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases.

Authors:  Pascal Peschard; Morag Park
Journal:  Cancer Cell       Date:  2003-06       Impact factor: 31.743

5.  An antisense oligodeoxynucleotide to p21(Waf1/Cip1) causes apoptosis in human breast cancer cells.

Authors:  Yaping Fan; Alexander D Borowsky; Robert H Weiss
Journal:  Mol Cancer Ther       Date:  2003-08       Impact factor: 6.261

6.  AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol.

Authors:  Shubha Anand; Sue Penrhyn-Lowe; Ashok R Venkitaraman
Journal:  Cancer Cell       Date:  2003-01       Impact factor: 31.743

Review 7.  p21Waf1/Cip1 as a therapeutic target in breast and other cancers.

Authors:  Robert H Weiss
Journal:  Cancer Cell       Date:  2003-12       Impact factor: 31.743

8.  Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex.

Authors:  Maina Lepourcelet; Ying-Nan P Chen; Dennis S France; Huisheng Wang; Phillip Crews; Frank Petersen; Charles Bruseo; Alexander W Wood; Ramesh A Shivdasani
Journal:  Cancer Cell       Date:  2004-01       Impact factor: 31.743

9.  Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian cells.

Authors:  Tomotoshi Marumoto; Toru Hirota; Tetsuro Morisaki; Naoko Kunitoku; Dongwei Zhang; Yasuko Ichikawa; Takashi Sasayama; Shinji Kuninaka; Tatsuyuki Mimori; Norihiko Tamaki; Masashi Kimura; Yukio Okano; Hideyuki Saya
Journal:  Genes Cells       Date:  2002-11       Impact factor: 1.891

10.  Metaphase arrest with centromere separation in polo mutants of Drosophila.

Authors:  M M Donaldson; A A Tavares; H Ohkura; P Deak; D M Glover
Journal:  J Cell Biol       Date:  2001-05-14       Impact factor: 10.539

View more
  4 in total

1.  Second Generation Small Molecule Inhibitors of Gankyrin for the Treatment of Pediatric Liver Cancer.

Authors:  Amber M D'Souza; Manu Gnanamony; Maria Thomas; Peter Hanley; Dipti Kanabar; Pedro de Alarcon; Aaron Muth; Nikolai Timchenko
Journal:  Cancers (Basel)       Date:  2022-06-22       Impact factor: 6.575

2.  Dispirooxindole-β-Lactams: Synthesis via Staudinger Ketene-Imine Cycloaddition and Biological Evaluation.

Authors:  Vadim E Filatov; Dmitrii A Iuzabchuk; Viktor A Tafeenko; Yuri K Grishin; Vitaly A Roznyatovsky; Dmitrii A Lukianov; Yulia A Fedotova; Maxim A Sukonnikov; Dmitry A Skvortsov; Nikolai V Zyk; Elena K Beloglazkina
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

Review 3.  Tumor Profiling at the Service of Cancer Therapy.

Authors:  Ceres Fernandez-Rozadilla; Ana Rita Simões; Matilde E Lleonart; Amancio Carnero; Ángel Carracedo
Journal:  Front Oncol       Date:  2021-01-11       Impact factor: 6.244

Review 4.  Recent Advances in the Biological Activity of s-Triazine Core Compounds.

Authors:  Dawid Maliszewski; Danuta Drozdowska
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.